Efficient immune responses against Intimin and EspB of enterohaemorragic Escherichia coli after intranasal vaccination using the TLR2/6 agonist MALP-2 as adjuvant

CATALDI ANGEL; YEVSA TETYANA; VILTE DANIEL; SCHULZE KAI; CASTRO PARODI MAURICIO; LARZÁBAL MARIANO; IBARRA CRISTINA; MERCADO ELSA; GUZMÁN CARLOS A

VACCINE

ELSEVIER SCI LTD

Año: 2008 vol. 26 p. 5662 - 5667

0264-410X

Mucosal vaccine formulations based on purified recombinant C280 -Intimin and EspB (Escherichia colisecreted protein B) from enterohaemorragic E. coli co-administered with a pegylated derivative of theTLR2/6 agonist MALP-2 (macrophage-activating lipopeptide) as adjuvant were evaluated in BALB/c mice.After intranasal vaccination, strong humoral and cellular immune responses were observed against C280-Intimin and EspB. Sera of immunized mice inhibit bacterial haemolytic activity in vitro. Antigen-specificT-cell proliferation, IL-4, IL-2 and IFN- producing cells, and secretory IgAwere mostly detected in animalsreceiving MALP-2 as adjuvant. These results suggest that C280 -Intimin and EspB are good candidateantigens to be incorporated into mucosal vaccines against this important pathogen.